The investigators grouped patients in the positive MRD cohort with different types of response together, making it difficult to directly compare MRD status between de novo CML-BP and Ph-positive ALL.

The meta-analysis developed sense of the pooled effect this factor had on survival, indicating that patients with MRD negative status experienced a 20% reduced risk of death compared with patients ...

Findings showed 30% of patients in the ponatinib arm achieved MRD-negative CR rate at the end of the induction phase compared with 12% of those in the imatinib arm (risk difference, 0.18 [95% CI ...

Most (77%) also reported that they consider MRD negativity an acceptable end point in clinical trials; 18% preferred the use of overall survival, and 5% preferred progression-free survival. 3 ...

Advances in tyrosine kinase inhibitors yielded robust options for CML, raising questions about US accelerated approval for the frontline use of asciminib in this indication.